Biopool Says 3rd-Quarter Sales Improved in ’99

Biopool International in Ventura reported that sales for the third quarter ended Sept. 30 were $2 million, compared with $1.7 million for the same period last year. Net income for the quarter was $77,000 or 1 cent per diluted share, compared with $43,000 and no per-share gain for the same period in 1998.

Biopool develops and manufactures test kits to assess and diagnose blood disorders and specialty toxicology controls to monitor and measure the presence of drugs. The company’s product line is sold to hospitals, clinical laboratories, commercial reference laboratories and research institutions.